Effects of troglitazone on insulin sensitivity in HIV-infected patients with protease inhibitor-associated diabetes mellitus

No abstract is available for this paper.

• Publication year

  1999

• Venue

  Research in experimental medicine. Zeitschrift fur die gesamte experimentelle Medizin einschliesslich experimenteller Chirurgie

• Publication date

  1999-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/S004330050123PMID 10815754
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy.

  1999cited by this paper
• Insulin resistance syndrome: options for treatment.

  1999cited by this paper
• Effects of metformin on insulin resistance and central adiposity in patients receiving effective protease inhibitor therapy.

  1999cited by this paper
• Hyperlipidemia under treatment with proteinase inhibitors

  1999cited by this paper
• Insulin resistance: current concepts.

  1998cited by this paper
• HIV risk behavioral surveillance: a methodology for monitoring behavioral trends.

  1998cited by this paper
• The Role of Troglitazone in Treating the Insulin Resistance Syndrome

  1998cited by this paper
• Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus.

  1998cited by this paper
• Body shape changes in HIV-infected patients.

  1998cited by this paper
• Indinavir‐associated lipodystrophy

  1998cited by this paper
• PPAR-gamma: adipogenic regulator and thiazolidinedione receptor.

  1998cited by this paper
• Disorders of fat distribution in HIV infection

  1998cited by this paper
• A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors

  1998cited by this paper
• Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. Troglitazone and Exogenous Insulin Study Group.

  1998cited by this paper
• Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV‐1‐infected patients

  1998cited by this paper
• Cardiac and Glycemic Benefits of Troglitazone Treatment in NIDDM

  1997cited by this paper
• Effects of troglitazone and metformin on glucose and lipid metabolism: alterations of two distinct molecular pathways.

  1997cited by this paper
• Erratum to: Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients

  1996cited by this paper
• Lipoprotein lipase and lipolysis: central roles in lipoprotein metabolism and atherogenesis.

  1996cited by this paper
• Validation of the low dose short insulin tolerance test for evaluation of insulin sensitivity

  1994cited by this paper
• Lipoprotein Lp(a) as predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors: results from the prospective Göttingen Risk Incidence and Prevalence Study (GRIPS)

  1994cited by this paper
• Effects of metformin on haemorheology, lipid parameters and insulin resistance in insulin-dependent diabetic patients (IDDM).

  1991cited by this paper
• Estimation of extracellular and total body water by multiple-frequency bioelectrical-impedance measurement.

  1991cited by this paper
• Metformin Revisited: Its Actions and Indications for Use

  1988cited by this paper

• Prevalence, underlying mechanisms and role of nutrition in the management of the HIV-associated lipodystrophy syndrome

  2015influential citation
• Plasma metabolomics identifies lipid abnormalities linked to markers of inflammation, microbial translocation, and hepatic function in HIV patients receiving protease inhibitors

  2013influential citation
• Metabolic Complications Associated with HIV Protease Inhibitor Therapy

  2012cites this paper
• PPARs in Viral Disease

  2009cites this paper
• Treatment options for lipodystrophy in HIV-positive patients

  2008cites this paper
• Pathogenesis and treatment of lipodystrophy: what clinicians need to know.

  2008cites this paper
• The Effects of Thiazolidinediones on Metabolic Complications and Lipodystrophy in HIV-Infected Patients

  2008cites this paper
• Clinical aspects of toxicity in antiretroviral therapy

  2008cites this paper
• Pharmacologic Factors Affecting Glycemic Control

  2008cites this paper
• HIV lipodystrophy and its metabolic consequences: implications for clinical practice

  2008cites this paper
• Recombinant Human Growth Hormone to Treat HIV-Associated Adipose Redistribution Syndrome: 12-Week Induction and 24-Week Maintenance Therapy

  2007cites this paper
• Effect of rosiglitazone and metformin on insulin resistance in patients infected with human immunodeficiency virus receiving highly active antiretroviral therapy containing protease inhibitor: randomized prospective controlled clinical trial.

  2007cites this paper
• Use of metabolic drugs and fish oil in HIV‐positive patients with metabolic complications and associations with dyslipidaemia and treatment targets

  2007cites this paper
• Thiazolidinediones in dermatology

  2007cites this paper
• Leptin and Adiponectin in the HIV Associated Metabolic Syndrome: Physiologic and Therapeutic Implications.

  2006cites this paper
• Appendix to the German-Austrian HIV Therapeutic Guidelines: strategies for treating morphological and metabolic alterations under antiretroviral treatment (current as of December 2004).

  2006cites this paper
• Treatment of AIDS Anorexia-Cachexia Syndrome and Lipodystrophy

  2006cites this paper
• Protease Inhibitor-Induced Diabetic Complications

  2005cites this paper
• Effect of metformin and rosiglitazone on lipid metabolism in HIV infected patients receiving protease inhibitor containing HAART.

  2005cites this paper
• Influence of Rosiglitazone on Flow-Mediated Dilation and Other Markers of Cardiovascular Risk in HIV-Infected Patients with Lipoatrophy

  2005cites this paper
• Cellular mechanisms of insulin resistance, lipodystrophy and atherosclerosis induced by HIV protease inhibitors.

  2005cites this paper
• Interventions for managing antiretroviral therapy-associated lipoatrophy

  2005cites this paper
• Update on HIV Lipodystrophy

  2004cites this paper
• [Metabolic abnormalities in patients with HIV infection].

  2004cites this paper
• Lipids, lipodystrophy, and AIDS

  2004cites this paper
• Thiazolidinediones as PPAR Agonists

  2004cites this paper
• No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial.

  2004cites this paper
• Ai1812co 1741..1749

  2004cites this paper
• ANORMALIDADES METABÓLICAS EN PACIENTES CON INFECCIÓN POR VIH

  2004cites this paper
• Effects of Growth Hormone on Abnormal Visceral Adipose Tissue Accumulation and Dyslipidemia in HIV-Infected Patients

  2004cites this paper
• Management of Dyslipidaemia in HIV-Infected Patients Receiving Antiretroviral Therapy

  2004cites this paper
• Proximal tubular kidney damage and tenofovir: a role for mitochondrial toxicity?

  2004cites this paper
• Development of multiple lipomas during treatment with rosiglitazone in a patient with HIV-associated lipoatrophy.

  2004cites this paper
• Clinical review 159: Human immunodeficiency virus/highly active antiretroviral therapy-associated metabolic syndrome: clinical presentation, pathophysiology, and therapeutic strategies.

  2003cites this paper
• [The HIV protease inhibitor-induced insulin resistance syndrome].

  2003cites this paper
• Intramyocellular lipid accumulation and reduced whole body lipid oxidation in HIV lipodystrophy.

  2003cites this paper
• Insulin resistance in HIV-related lipodystrophy

  2003cites this paper
• Mechanisms for the deterioration in glucose tolerance associated with HIV protease inhibitor regimens.

  2003cites this paper
• Evaluation and management of metabolic and coagulative disorders in HIV-infected patients receiving highly active antiretroviral therapy.

  2003cites this paper
• HIV Protease Inhibitor Ritonavir Induces Lipoatrophy in Male Mice

  2003cites this paper
• Lipodystrophy, insulin resistance, diabetes mellitus, dyslipidemia, and cardiovascular disease in human immunodeficiency virus infection.

  2003cites this paper
• Antiretroviral therapy in HIV patients: aspects of metabolic complications and mitochondrial toxicity.

  2003cites this paper
• Nutritional aspects of HIV-infected children receiving highly active antiretroviral therapy

  2003cites this paper
• Glitazones in lipodystrophy syndrome induced by highly active antiretroviral therapy.

  2003cites this paper
• [Adverse effects of antiretroviral therapy. Aspects of pathogenesis].

  2003cites this paper
• Nutrition and Metabolism in HIV-1-Infected Children Receiving Haart Therapy

  2003cites this paper
• Human Immunodeficiency Virus/Highly Active Antiretroviral Therapy-Associated Metabolic Syndrome: Clinical Presentation, Pathophysiology, and Therapeutic Strategies

  2003cites this paper
• Pathogenesis and treatment of lipodystrophy in hiv-infected patients receiving highly active antiretroviral therapy

  2003cites this paper
• 159 Human Immunodeficiency Virus / Highly Active Antiretroviral Therapy-Associated Metabolic Syndrome : Clinical Presentation , Pathophysiology , and Therapeutic Strategies

  2003cites this paper
• Featured CME Topic: Lipodystrophy Syndrome in HIV Infection Lipodystrophy, Insulin Resistance, Diabetes Mellitus, Dyslipidemia, and Cardiovascular Disease in Human Immunodeficiency Virus Infection

  2003cites this paper
• Thiazolidinediones: A Review of Their Benefits and Risks

  2002cites this paper
• Tiazolidinedionas. Beneficios y riesgos reales

  2002cites this paper
• Improved Insulin Sensitivity and Body Fat Distribution in HIV‐Infected Patients Treated With Rosiglitazone: A Pilot Study

  2002cites this paper
• Nutritional interventions in pediatric HIV: it's hard to hit a moving target.

  2002cites this paper
• Thiazolidinediones in the treatment of Type 2 diabetes

  2002cites this paper
• Lipodystrophy in Human Immunodeficiency Virus-Infected Patients

  2002cites this paper
• Recomendaciones de GESIDA/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en pacientes adultos infectados por el virus de la inmunodeficiencia humana en el año 2002

  2002cites this paper
• Improved insulin sensitivity and body fat distribution in HIV-infected patients treated with rosiglitazone: a pilot study.

  2002cites this paper
• Body-composition measurements as predictors of glucose and insulin abnormalities in HIV-positive men.

  2002cites this paper
• Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance.

  2002cites this paper
• CD36 deficiency induced by antiretroviral therapy

  2002cites this paper
• Thiazolidinediones Could Improve Endothelial Dysfunction and Risk of Premature Coronary Heart Disease in HIV-Infected Patients

  2002cites this paper
• Insulin resistance and HIV-related lipoatrophy.

  2002cites this paper
• Selected metabolic and morphologic complications associated with highly active antiretroviral therapy.

  2002cites this paper
• HIV-associated lipodystrophy: Description, pathogenesis, and molecular pathways

  2002cites this paper
• [Recommendations of the Spanish AIDS Study Group (GESIDA) and the National Aids Plan (PNS) for antiretroviral treatment in adult patients with human immunodeficiency virus infection in 2002].

  2002cites this paper
• The metabolic abnormalities associated with non-alcoholic fatty liver disease.

  2002cites this paper
• Clinical review 153: Lipodystrophy in human immunodeficiency virus-infected patients.

  2002cites this paper
• Strategies for treating HIV-related lipodystrophy

  2001cites this paper
• Improvement of HAART-associated insulin resistance and dyslipidemia after replacement of protease inhibitors with abacavir.

  2001cites this paper
• HIV Lipodystrophy: Review of the Syndrome and Report of a Case Treated with Liposuction

  2001cites this paper
• Synergistic Antiadipogenic Effects of HIV Type 1 Protease Inhibitors with Tumor Necrosis Factor α: Suppression of Extracellular Insulin Action Mediated by Extracellular Matrix-Degrading Proteases

  2001cites this paper
• Selective aspects of the insulin resistance syndrome

  2001cites this paper
• Drug-induced hyperglycemia.

  2001cites this paper
• Antiretroviral therapy-associated hyperlipidaemia in HIV disease

  2001cites this paper
• The HIV protease inhibitor nelfinavir induces insulin resistance and increases basal lipolysis in 3T3-L1 adipocytes.

  2001cites this paper
• Nutritional management of HIV in the era of highly active antiretroviral therapy: a review of treatment strategies

  2001cites this paper
• Metabolic complications associated with antiretroviral therapy.

  2001cites this paper
• Lipodystrophy Syndrome in Patients with HIV Infection

  2001cites this paper
• Lipodystrophy and metabolic disorders as complication of antiretroviral therapy of HIV infection.

  2001cites this paper
• Management of antiretroviral-related nutritional problems: state of the science.

  2001cites this paper
• CONTINUING EDUCATION OFFERING

  2001cites this paper
• Adverse metabolic consequences of HIV protease inhibitor therapy: the search for a central mechanism.

  2001cites this paper
• Troubles métaboliques associés aux traitements de l'infection par le virus de l'immunodéficience humaine (VIH)

  2000cites this paper
• [Metabolic complications of antiretroviral therapy of HIV infection].

  2000cites this paper
• [Metabolic changes in anti-HIV therapy].

  2000cites this paper
• Metabolische Veränderungen unter einer Anti-HIV-Therapie

  2000cites this paper